Exploring T-Cell Fitness Strategies to Optimize Clinical Outcomes in RRMM

EP: 1.Exploring the Treatment Options for RRMM

EP: 2.Sequencing the Available T Cell– Engaging Therapies, and the Role of Bridging/Holding Therapy in RRMM

Now Viewing

EP: 3.Exploring T-Cell Fitness Strategies to Optimize Clinical Outcomes in RRMM

EP: 4.Discussing the Treatment Options for RRMM Following Progression After BCMA CAR T Therapy

EP: 5.Important Patient and Clinical Considerations When Choosing Therapy in RRMM Following CAR T Therapy

EP: 6.Highlighting Selinexor in the RRMM Setting After CAR T Therapy

EP: 7.Bispecific Antibodies for the Treatment of RRMM in the Post CAR T Setting

EP: 8.Practical Recommendations for Community Oncologists Treating RRMM

Physician Summary: Bridging Strategies to Preserve or Enhance T-Cell Fitness Prior to CAR T

T-cell fitness is a key determinant of CAR T therapy success. Certain bridging strategies may help preserve or even enhance T-cell function during the waiting period before CAR T infusion.

Helpful Bridging Strategies:

• Selinexor: Has shown immunomodulatory effects on the tumor microenvironment and may enhance T-cell function, according to emerging data. It’s a viable option for disease control without significant T-cell suppression.
• IMiDs (eg, pomalidomide): Can support T-cell activation and persistence, and may boost CAR T efficacy when used prior to infusion.
• Immune checkpoint inhibitors (eg, nivolumab): Early data suggest potential to restore exhausted T cells and improve CAR T outcomes, though this remains investigational.

Key Takeaway: When bridging is required, selecting agents like selinexor, IMiDs, or possibly ICIs may offer dual benefit—disease control and preservation of T-cell fitness—improving the likelihood of a successful CAR T response.